Prognostic value of mesothelin expression in patients with triple negative and HER2-positive breast cancers

Bayoglu I. V., Kucukzeybek B. B., Kucukzeybek Y., Varol U., Yildiz İ., Alacacioglu A., ...Daha Fazla

BIOMEDICINE & PHARMACOTHERAPY, cilt.70, ss.190-195, 2015 (SCI-Expanded) identifier identifier identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 70
  • Basım Tarihi: 2015
  • Doi Numarası: 10.1016/j.biopha.2015.01.019
  • Dergi Adı: BIOMEDICINE & PHARMACOTHERAPY
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Sayfa Sayıları: ss.190-195
  • Anahtar Kelimeler: Mesothelin, Cell surface proteins, Breast cancer, Her-2/Neu positive, Triple negative, Cell survival/proliferation, EPITHELIAL OVARIAN-CARCINOMA, PANCREATIC-CANCER, MONOCLONAL-ANTIBODY, CELL-PROLIFERATION, SEROUS CARCINOMA, GASTRIC-CANCER, SURVIVAL, TARGET, OVEREXPRESSION, IMMUNOTHERAPY
  • Acıbadem Mehmet Ali Aydınlar Üniversitesi Adresli: Hayır

Özet

Purpose: Mesothelin is a cell surface glycoprotein that is overexpressed in various malignancies. Recent studies have revealed that mesothelin plays an oncogenic role in tumor growth and drug resistance through the Wnt/NF-kappa B/PI3K/Akt signaling pathways. Herein, the expression of mesothelin in HER2-positive and triple-negative breast cancer (TNBC) has been correlated with prognosis.